top of page

Orphan drug designation granted to Boehringer Ingelheim’s systemic sclerosis drug

The European Commission (EC) and US Food and Drug Administration (FDA) have both granted orphan drug designation to Boehringer Ingelheim’s nintedanib for the treatment of systemic sclerosis (SSc, also known as scleroderma), including the associated interstitial lung disease (SSc-ILD).

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page